Finally, analysts at Deutsche Bank raised their price target on shares of St. Jude Medical from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Two research analysts have rated the stock with a sell ...
Once complete, the acquisition of Spinal Modulation, Inc. will further support St. Jude Medical's mission to help physicians tailor treatment to a patient's chronic pain condition to achieve superior outcomes.
St. Jude Medical, Inc. (NYSE:STJ) 74.27 -0.47 -0.63% director and an insider Barbara Hill a few days ago sold 3,229 company shares having a total value $229,711 at an avg stock price per share of $71.1.
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced Health Canada approval and first implant in Canada of its Prodigy™ Chronic Pain System with Burst technology.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the presentation of important data around its SJM™ Quadra CRT System during the Heart Rhythm Society's (HRS) 36th annual scientific sessions.